Mitchell Rosner
Nephrology · Charlottesville, VANPI 1164591707
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), grants and speaking fees — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Baxter Healthcare at 49.8% of the total. Reporting peaked in 2019 at $61,541 and has fallen 91.9% since, to $4,960 in 2024. Among nephrology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $1318.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$52K
- Medtronic$25K
- Travere Therapeutics, Inc.$11K
- Astrazeneca UK Limited$8K
- Astute Medical, Inc.$4K
- Sanofi$3K
- plus $3K from 4 others
Across 11 payments — averaging $17,641 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kadmon Corporation LLC$172K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$21K
- Biomerieux Inc$963
What the payments were for
- Consulting fees$49,07547%
- Speaking & faculty fees$18,55718%
- Grants$24,70623%
- Travel & lodging$10,53910%
- Food & beverage$6761%
- Education$1,8982%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 40 | $52,491 |
| Medtronic | 1 | $24,706 |
| Travere Therapeutics, Inc. | 17 | $10,571 |
| Astrazeneca UK Limited | 5 | $8,200 |
| Astute Medical, Inc. | 11 | $3,817 |
| Sanofi | 1 | $2,877 |
| Calliditas Therapeutics US Inc. | 2 | $2,504 |
| AstraZeneca | 1 | $200 |
| Novartis | 1 | $59 |
| BD | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - Sharesource$24,168
- Renal - PD$23,420
- TARPEYO$2,500
- Renal - Theranova$2,326
- Renal - Chronic$1,190
- NEPHROCHECK Liquid Control Kit$1,167
- Renal - Revaclear$862
- NEPHROCHECK TEST$650
How this compares
$105,451 in reported general payments places this provider in the 95th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 13 | $20,186 |
| Potassium Chloride | 22 | $620 |
| Losartan Potassium | 17 | $231 |
| Amlodipine Besylate | 21 | $173 |
| Furosemide | 13 | $172 |
| Lisinopril | 16 | $108 |
| Carvedilol | 11 | $39 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Charlottesville
- Rasheed BalogunCharlottesville$24K
- Swati RaoCharlottesville$10K
- Mark OkusaCharlottesville$9K
- Ramon MendezWoodbridge$791K
- Reza ZonoziFairfax$262K
- Sandeep MagoonNorfolk$204K
- Thomas McCuneNorfolk$202K
- Gaurav GuptaRichmond$168K
- Csaba KovesdySalem$152K
- Ramin TolouianNorfolk$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.